OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Public ClinicalTrials.gov record NCT03746483. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Multicenter, 2x2 Crossover Trial to Assess the Safety and Efficacy of MS1819-SD in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Study identification
- NCT ID
- NCT03746483
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Entero Therapeutics
- Industry
- Enrollment
- 41 participants
Conditions and interventions
Interventions
- MS1819 Drug
- Porcine PERT Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 9, 2019
- Primary completion
- Jul 12, 2019
- Completion
- Jul 26, 2019
- Last update posted
- Jun 5, 2022
2019
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 105 | Long Beach | California | 90806 | — |
| Investigator Site 102 | Altamonte Springs | Florida | 32701 | — |
| Investigator Site 107 | Miami | Florida | 33136 | — |
| Investigator Site 101 | Glenview | Illinois | 60025 | — |
| Investigator Site 111 | Wichita | Kansas | 67214 | — |
| Investigator Site 108 | Portland | Maine | 04102 | — |
| Investigator Site 103 | Las Vegas | Nevada | 89109 | — |
| Investigator Site 110 | Cleveland | Ohio | 44106 | — |
| Investigator Site 104 | Toledo | Ohio | 43606 | — |
| Investigator Site 106 | Hershey | Pennsylvania | 17033 | — |
| Investigator Site 109 | Dallas | Texas | 75235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03746483, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2022 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03746483 live on ClinicalTrials.gov.